Search results
Showing 8251 to 8265 of 8314 results
Hundreds of people with multiple myeloma could receive a new, targeted treatment recommended for use within the Cancer Drugs Fund today (Tuesday, 29 October).
Heart failure patients to be remotely monitored by technology shown to cut hospitalisations by 50%
Two technologies, HeartLogic and TriageHF, have been recommended in final diagnostic guidance.
Draft guidance issued for consultation recommends the use of 4 AI technologies to help professionals detect fractures in urgent care settings.
New Alzheimer's treatment donanemab does not currently demonstrate value for the NHS says NICE
More evidence is needed on the clinical and cost-effectiveness of donanemab, a new treatment for mild Alzheimer’s disease.
NICE recommends new treatment to prevent and reduce hearing loss in people being treated for cancer
For the first time, NICE has recommended an innovative new treatment to help stop babies, children and young people who are undergoing cancer treatment from losing their hearing.
Over 1000 people with advanced breast cancer set to benefit from new once-a-day tablet
We’ve issued final draft guidance recommending a new once-a-day tablet that is set to benefit around 1,100 people with a type of advanced breast cancer.
Public consultation launched on changes to NICE's Highly Specialised Technologies routing criteria
NICE is proposing changes to its routing criteria for Highly Specialised Technologies (HST) to ensure more consistent, predictable and transparent decisions.
New price deal paves way for NICE approval of treatment for rare genetic condition
A new treatment for Duchenne muscular dystrophy (DMD) is set to be available to around 1,700 people in England following positive final draft guidance from NICE published today.
For the first time, the British Thoracic Society (BTS), National Institute for Health and Care Excellence (NICE) and the Scottish Intercollegiate Guidelines Network (SIGN) have collaborated to develop a UK-wide asthma guideline.
NICE responds to failure of talks to reach price agreement on Enhertu
Talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged.
Towards a new partnership – NICE and the voluntary and community sector
Victoria Thomas gives details of NICE’s new voluntary and community sector forum.
"Tell me and I forget. Teach me and I remember. Involve me and I learn." Benjamin Franklin.
More people with rare genetic disorder eligible for nusinersen
Following a review of data collected as part of the Managed Access Agreement, more people with spinal muscular atrophy (SMA) are to benefit from nusinersen.
Public consultation on updates to health technology evaluations manual
A public consultation marking the first update to NICE's health technology evaluations manual is now open.
NICE issues draft guidance for public consultation which does not recommend Evusheld for preventing COVID-19 in some adults.